Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Tamzor - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Tamzor

Approved

STANDARD

Tamzor

Lek Pharmaceuticals D.D.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 6cfa6d1debb1a9c4
Company: Lek Pharmaceuticals D.D.
Type: Standard

Approval Details

Approval Id: 6cfa6d1debb1a9c4
Drug Approval Philippines Name: Tamzor
Product Name: Tamzor
Registration Number: DRP-2667-01
Brand Name: Tamzor
Generic Name: Tamsulosin Hydrochloride
Dosage Form: Extended-Release Capsule
Dosage Strength: 400 mcg
Manufacturer: Lek Pharmaceuticals D.D.
Importer: Sandoz Philippines Corporation
Distributor: The Cathay Drug Co., Inc.
Company Detail Path: /organization/lek-pharmaceuticals-dd
Issuance Date: 26 February 2021
Expiry Date: 03 January 2026
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

6cfa6d1debb1a9c4

Type

Standard

Back to Philippines FDA Approvals